[go: up one dir, main page]

DK1408968T3 - Receptoradapteret nikotinafvænning gennem en kombination af atropin, scopolamin, clonidin - Google Patents

Receptoradapteret nikotinafvænning gennem en kombination af atropin, scopolamin, clonidin

Info

Publication number
DK1408968T3
DK1408968T3 DK02753025T DK02753025T DK1408968T3 DK 1408968 T3 DK1408968 T3 DK 1408968T3 DK 02753025 T DK02753025 T DK 02753025T DK 02753025 T DK02753025 T DK 02753025T DK 1408968 T3 DK1408968 T3 DK 1408968T3
Authority
DK
Denmark
Prior art keywords
atropine
scopolamine
clonidine
combination
patch
Prior art date
Application number
DK02753025T
Other languages
English (en)
Inventor
Wolfgang J Kox
Mario Hensel
Original Assignee
Wolfgang J Kox
Mario Hensel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wolfgang J Kox, Mario Hensel filed Critical Wolfgang J Kox
Application granted granted Critical
Publication of DK1408968T3 publication Critical patent/DK1408968T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02753025T 2001-07-25 2002-07-18 Receptoradapteret nikotinafvænning gennem en kombination af atropin, scopolamin, clonidin DK1408968T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10136228A DE10136228A1 (de) 2001-07-25 2001-07-25 Rezeptoradaptierter Nikotinetzug durch anticholinerge und noradrenerge Blockade

Publications (1)

Publication Number Publication Date
DK1408968T3 true DK1408968T3 (da) 2006-03-27

Family

ID=7693048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02753025T DK1408968T3 (da) 2001-07-25 2002-07-18 Receptoradapteret nikotinafvænning gennem en kombination af atropin, scopolamin, clonidin

Country Status (7)

Country Link
EP (1) EP1408968B1 (da)
AT (1) ATE310520T1 (da)
CY (1) CY1107651T1 (da)
DE (4) DE10136228A1 (da)
DK (1) DK1408968T3 (da)
ES (1) ES2254709T3 (da)
WO (1) WO2003015782A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145874A1 (en) * 2006-06-08 2007-12-21 Hythiam, Inc. Anti-nicotine treatment comprising use of three anticholinergic agents
EP2095814A1 (de) 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
CN103494810A (zh) * 2013-09-25 2014-01-08 青岛市市立医院 治疗网络成瘾的药物组合物
KR102729111B1 (ko) * 2021-09-28 2024-11-13 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4555397A (en) * 1983-08-12 1985-11-26 Nicholas Bachynsky Method for anti-cholinergic blockage of withdrawal symptoms in smoking cessation
US4788189A (en) * 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
CA2220768A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US6132754A (en) * 1999-02-23 2000-10-17 Hudson; Paul J. Method for helping a patient eliminate tobacco dependency
AU5397300A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich

Also Published As

Publication number Publication date
ES2254709T3 (es) 2006-06-16
ATE310520T1 (de) 2005-12-15
DE10136228A1 (de) 2003-03-06
WO2003015782A2 (de) 2003-02-27
DE10293600B4 (de) 2005-08-25
DE50205046D1 (de) 2005-12-29
CY1107651T1 (el) 2012-05-23
WO2003015782A3 (de) 2003-08-07
EP1408968A2 (de) 2004-04-21
DE20205918U1 (de) 2002-12-05
DE10293600D2 (de) 2004-08-05
EP1408968B1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
PT1729730E (pt) Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso
ES2534294T3 (es) Métodos para tratar la preeclampsia
DE60116256D1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
MY141651A (en) Nep inhibitors for the treatment of female sexual dysfunction
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
DE60320770D1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
MA24794A1 (fr) D-methadone, un analgesique nonopioique
DK1408968T3 (da) Receptoradapteret nikotinafvænning gennem en kombination af atropin, scopolamin, clonidin
Branda et al. Role of brain dynorphin in nitrous oxide antinociception in mice
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
YU89003A (sh) Prevencija zavisnosti u terapiji bola
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
CN1069196C (zh) 利福平在制备治疗淋病用的药物中的应用
WO2008157335A3 (en) Methods for the treatment of erectile dysfunction using fispemifene
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
WO2002036071A3 (en) Method of treating and preventing migraine headaches
CO5170459A1 (es) Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
WO2007062048A3 (en) Role of proteoglycans in drug dependence
WO2005030931A3 (en) Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
DE602004021395D1 (de) Verfahren zur behandlung von hepatozellulärem karzinom
UA39283U (ru) Способ лечения перитонита в послеоперационном периоде
WO2006024044A3 (en) Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrostone